Table 1 Clinical characterization of participants in the CT, SCLC, and NSCLC groups.
Characteristics | Screening | Verification | Total | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
CT group (n = 15) | SCLC group (n = 10) | NSCLC group (n = 10) | p | CT group (n = 9) | SCLC group (n = 15) | NSCLC group (n = 15) | p | CT group (n = 24) | SCLC group (n = 25) | NSCLC group (n = 25) | p | |
Sex | 0.312 | 1.000 | 0.417 | |||||||||
Male | 7 | 8 | 5 | 7 | 11 | 12 | 14 | 19 | 17 | |||
Female | 8 | 2 | 5 | 2 | 4 | 3 | 10 | 6 | 8 | |||
Age | 66.1 ± 6.4 | 58.6 ± 7.3 | 63.2 ± 10.3 | 0.084 | 60.6 ± 8.4 | 63.7 ± 8.4 | 64.9 ± 6.0 | 0.401 | 64.0 ± 7.5 | 61.7 ± 8.2 | 64.2 ± 7.8 | 0.459 |
Smoking history | 1.000 | 0.741 | 0.805 | |||||||||
Yes | 5 | 3 | 3 | 2 | 4 | 6 | 7 | 7 | 9 | |||
No | 10 | 7 | 7 | 7 | 11 | 9 | 17 | 18 | 16 | |||
Lung cancer TNM staging | ||||||||||||
T | 0.628 | 1.000 | 0.758 | |||||||||
1 | – | 6 | 8 | – | 11 | 10 | – | 17 | 18 | |||
2 | – | 4 | 2 | – | 4 | 5 | – | 8 | 7 | |||
N | 1.000 | 1.000 | 0.747 | |||||||||
0 | – | 3 | 2 | – | 4 | 3 | – | 7 | 6 | |||
1 | – | 7 | 8 | – | 11 | 12 | – | 18 | 19 | |||
Stage | 1.000 | 1.000 | 0.508 | |||||||||
I | – | 3 | 2 | - | 4 | 3 | – | 7 | 5 | |||
II | – | 7 | 8 | - | 11 | 12 | – | 18 | 20 | |||
Pathology(NSCLC) | ||||||||||||
Adenocarcinoma | – | – | 7 | – | – | – | 8 | – | – | – | – | 15 |
Squamous cell carcinoma | – | – | 3 | – | – | – | 7 | – | – | – | – | 10 |
